Janux Therapeutics Inc (JANX)
47.11
-0.40
(-0.84%)
USD |
NASDAQ |
May 17, 16:00
47.11
0.00 (0.00%)
After-Hours: 20:00
Janux Therapeutics Research and Development Expense (Quarterly): 14.07M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 14.07M |
| December 31, 2023 | 12.24M |
| September 30, 2023 | 11.89M |
| June 30, 2023 | 14.92M |
| March 31, 2023 | 15.86M |
| December 31, 2022 | 15.43M |
| September 30, 2022 | 13.74M |
| June 30, 2022 | 14.09M |
| March 31, 2022 | 10.18M |
| Date | Value |
|---|---|
| December 31, 2021 | 11.17M |
| September 30, 2021 | 8.406M |
| June 30, 2021 | 4.737M |
| March 31, 2021 | 1.925M |
| December 31, 2020 | 0.985M |
| September 30, 2020 | 0.834M |
| June 30, 2020 | 0.673M |
| March 31, 2020 | 0.549M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.549M
Minimum
Mar 2020
15.86M
Maximum
Mar 2023
8.924M
Average
11.17M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Viking Therapeutics Inc | 24.10M |
| Equillium Inc | 9.743M |
| Minerva Neurosciences Inc | 4.167M |
| Arvinas Inc | 84.30M |
| Calidi Biotherapeutics Inc | 3.958M |